

Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

N. FERRI, A. CORSINI, R. PONTREMOLI

Department of Medicine, University of Padua, Padua, Italy

Correction to: European Review for Medical and Pharmacological Sciences 2022; 26 (20): 7482–7492. DOI: 10.26355/eurrev_202210_30018-PMID: 36314318, published online on October 28, 2022.

After publication, the authors applied some corrections to the text:

- The section “Clinical Oharmacology of Lercanidipine” has been corrected into “Clinical Pharmacology of Lercanidipine”
- The Legend of Figure 2 has been corrected as follows: Ca T-type channels vs. Ca L-type channels selectivity ratio. LAC, lacidipine, AML, amlodipine; MIB, mibefradil; LER, lercanidipine; * $p < 0.05$, ** $p < 0.01$ vs. LAC (low concentrations); † $p < 0.01$ LAC vs. all other CCBs (high concentrations). Source: Modified from 25.
- The reference 25 has been changed into: Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? *Kidney Int* 2008; 73: 795-796.

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.